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1INTRODUCTION:
Metabolic Syndrome comprises a  group of risk factors for Cardio vascular
disease and diabetes and components of which  are Central obesity,
Hypertriglyceridemia , Hypertension, low levels of HDL cholesterol, and Glucose
intolerance. This syndrome is also known as syndrome X, the insulin resistance
syndrome, the deadly quartet, or the obesity dyslipidemia syndrome.
Persons with metabolic syndrome are 3 times more likely to develop
myocardial infarction and stroke than persons without Metabolic Syndrome and two
times more  likely to die from MI/STROKE  and  five times more  likely to develop
diabetes.Obesity is the most important component of the syndrome which  most likely
occurs before the development of other components of the syndrome. Atleast 3 out of
5components is needed to diagnose the Metabolic Syndrome.
COPD is characterised by obstruction to the airflow that is not fully reversible
and  there is no other explanation for the obstruction. According to the Global Burden
of Disease Study ,there are 25 million cases of COPD patients till 2016. Smoking is
the one of the important risk factor for thedevelopment of COPD.
Systemic inflammation plays an important role in development of both
Metabolic Syndrome and COPD. As said earlier, Metabolic Syndrome being the most
important factor in development of diabetes and MI, there is  an increased  need on
social and medical perspective for early diagnosis and management  of Metabolic
Syndrome in COPD patients ,Thereby we can advise people regarding life style
2modifications and   early treatment, thus reducing  the morbidity and mortality in
COPD patients. so this study is conducted to find the prevalence of Metabolic
Syndrome in COPD patients attending Thoracic Medicine outpatient department in
Government Vellore Medical College Hospital, Vellore.
3REVIEW OF LITERATURE
METABOLIC SYNDROME
HISTORY:
The term Metabolic Syndrome was first used by Herman Haller in 1977(2). In
1988 Gerald M.Reaven(3) in banting  lecture,  demonstrated a strong Correlation
between increased plasma insulin levels , glucose intolerance ,elevated VLDL, and
TGL, reduced  HDL and coined the term Metabolic Syndrome. In 1999, WHO
released a  first working definition of Metabolic  Syndrome(4).
EPIDEMIOLOGY OF METABOLIC SYNDROME:
According to IDF 20-25% of worlds adult population have the Metabolic
Syndrome. A study conducted by D.S.Prasad et al (5)on prevalence of Metabolic
Syndrome in Asian Indians  found  33.5% prevalence of Metabolic syndrome in urban
eastern India. In this study hypertension (63.1%) and elevated blood sugar 31.2% was
the most common and least common components observed  respectively. Another
study conducted in Kerala on prevalence of Metabolic Syndrome by S.Harikrishnan et
al (6) found it to be 24%  using NCEP ATP III criteria. They also found that
participants living in urban areas had higher prevalence of Metabolic Syndrome (26%)
than rural population(22%).
4VARIOUS CRITERIAS TO DIAGNOSE METABOLIC SYNDROME:
THE NEW IDF DEFINITION TO DIAGNOSE METABOLIC SYNDROME(7):
Person is said to have Metabolic Syndrome if they Have central obesity (waist
circumference > 90 cm in male and > 80cm in female in south east Asians) plus any
two of the following four parameters
1. Raised triglycerides ≥150mg/dl  or specific treatment for this abnormality
2. Reduced HDL cholesterol   <40mg/dl in males /<50mg/dl  in females or
specific treatment for this abnormality.
3. Raised Blood Preasure – Systolic BP ≥130 mmHg or Diastolic
BP≥85 mmHg or on drugs for hypertension.
4. Raised Fasting Blood Glucose ≥ 100mg/dl or previously diagnosed type 2
diabetes .
MODIFIED NCEP – ATP III DEFINITION FOR METABOLIC SYNDROME (8):
Person is said to have Metabolic Syndrome if 3 or more of the following
components were present
1. Central obesity - (waist circumference > 90 cm in male and > 80cm in female
in south east Asians)
2. High triglycerides ≥ 150mg/dl
3. Low HDL cholesterol - <40 mg/dl in males and <50 mg/dl in females
4. Elevated Blood Pressure ≥   130/85 mmHg or on treatment
5. Impaired fasting blood glucose ≥ 100mg/dl
5PATHOPHYSIOLOGY OF METABOLIC SYNDROME :
INTER RELATED FACTORS IN METABOLIC SYNDROME (9)
GENES
ACQUIRED
CONDITIONS
CARDIOVASCULAR DISEASETYPE 2 DM
OBEYSITY
VISCERAL
INSULIN RESISTANCE
OBESITY
6Insulin resistance and central obesity are the two important risk factors that plays the
Central role in the development of  metabolic syndrome
INSULIN RESISTANCE AND METABOLIC SYNDROME (10):
It is defined  as a subnormal biological  response to  a given concentration of
insulin. There are two types of insulin resistance.
PRIMARY RESISTANCE:
It is due to mutations affecting any protein between the receptor and the final
insulin regulated protein.
SECONDARY INSULIN RESISTANCE:
It is defined as  restoration of normal insulin sensitivity after removal of the
precipitating factors like glucagon / glucocorticoids / growth  hormone  or underlying
infection.
In 1992 Haffner et al (11) reported that insulin resistance leading to the fasting
hyperinsulinemia  preceded the  development of other components of Metabolic
Syndrome like Hypertension and Dyslipidemia . In a study conducted by Meigs et al
(12)in 2003  it is observed  that 25 -39%  of pre diabetic  patients  develop diabetes
over a period of 5 to 10 years.
7METABOLIC SYNDROME AND CENTRAL OBESITY:
Obesity is a common disease characterized by deposition of excess body fat.
Overweight and obesity are increasing in Asian Indians particularly in urban areas.
High body fat , abdominal adiposity, fatty liver predisposes   Asian Indians  to
develop  insulin resistance and metabolic syndrome early in their life. Easy access to
high caloric , low nutrient dense foods and sedentary life style strongly predisposes to
the development of metabolic syndrome.
Genetic factors related to obesity are rarely studied. One such study was
conducted on the Single nucleotide polymorphisms in the FTO gene and its
association with development of obesity by timothy M .Frayling et al (13)in 2007.
They found that SNPs in the FTO gene on chromosome 16 was  associated with
increased body mass index and diabetes. Hormones secreted by adipose tissue like
Adiponectin and Tumour necrosis factor -α (TNF – α)(14) play a key role in
development of Metabolic Syndrome.TNF α is elevated during weight gain and
reduced during weight loss. Both Adiponectin and TNF α  are antagonistic in
stimulating the NF-kB factor.
According to WHO report on obesity in 2008 (15), 1.5 billion adult population
were overweight  (BMI ≥ 25kg/m²) out of which 200 million  men and 300 million
women were obese (BMI≥30 kg/m²). In South East Asian countries prevalence of
overweight varies from 7.6% in adult males to 53% in adult females.
8CLASSIFICATION OF ADULTS ACCORDING TO BODY MASS INDEX(16)
CLASSIFICATION BMI (kg/m²)
RISK FOR NON
COMMUNICABLE
DISORDERS
UNDERWEIGHT < 18.50 LOW
NORMAL RANGE 18.50-24.99 AVERAGE
OVERWEIGHT ≥25.00
PREOBESE 25.00-29.99 INCREASED
OBESE CLASS I 30.00-34.99 MODERATE
OBESE CLASS II 35.00 -39.99 SEVERE
OBESE CLASS III ≥ 40.00 VERY SEVERE
9MECHANISM OF DEVELOPMENT METABOLIC SYNDROME IN
OBEYSIT (14)
OVERWEIGHT
INCREASED TNF α
NF-KB ACTIVATION
OXIDATIVE
STRESS
ADHESIONMOLECULES
INFLAMMATORY
CYTOKINES
DYSLIPIDEMIA
INSULIN
RESISTANCE/GLUCOSE
INTOLERANCE
ENDOTHELIAL
DYSFUNCTION
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FACTORS ASSOCIATED WITH OBESITY(9):
OBESITY
TYPE 2 DM
HYPERTENSION
CANCER
DYSLIPIDAEMIAATHEROSCLEROSIS
PCOS
METABOLIC
SYNDROME
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HYPERTENSION AND METABOLIC SYNDROME:
Hypertension is one of the important component of the Metabolic Syndrome. A
study conducted by geldsetzer et al(17) on  Hypertension and Diabetes in India
among 1.3 million adults found that prevalence of  hypertension Was  25.3% and it
was common even among people in younger age groups(18-25 years:12.1%).
Insulin  resistance  and obesity are the two important risk factors leading to
development of hypertension in Metabolic Syndrome.  Hyperinsulinemia and visceral
adiposity leads  to increased sympathetic activity and activation of renin- angiotensin-
aldosterone system  resulting in hypertension. Pankaj  J Akholkar et al (18)found that
44.5% of hypertensive patients had Metabolic Syndrome. Also prevalence of
hypertension in Metabolic Syndrome was higher in females of 62.62% compared to
males of 37.08%.
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CLASSIFICATION OF BLOOD PRESSURE IN ADULTS
(WHELTON ET AL)(19)
PUBLISHED IN JOURNAL OF THE AMERICAN COLLEGE OF
CARDIOLOGY
BLOOD
PRESSURE SYSTOLIC BP DIASTOLIC  BP
NORMAL <120mmHg                  and <80mmHg
ELEVATED 120-129mmHg             and <80mmHg
HYPERTENSION
STAGE 1 130-139mmHg or 80-89 mmHg
STAGE 2 ≥ 140mmHg                 or ≥90 mmHg
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MECHANISM OF DEVELOPMENT OF HYPERTENSION IN  METABOLIC
SYNDROME(20)
INSULIN RESISTENCE
HYPER INSULINEMIA
ACTIVATION OF SYMPHATHETIC NERVOUS
SYSTEM
INCREASED ACTIVITY OF SODIUM/HYDROGEN
PUMP
INCREASED RETENTION OF RENAL SODIUM
HYPERTENSION
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DYSLIPIDEMIA AND METABOLIC SYNDROME:
Dyslipidemia is one of the important risk factor for the development of
Metabolic Syndrome and its  complications like MI/stroke. It encompasses high low
density lipoprotein cholesterol, raised triglycerides and low high density lipoprotein
cholesterol and raised lipoprotein (a).
EPIDEMIOLOGY:
Multiple studies conducted in the India shows that prevalence of  dyslipidemia
(21)is  approximately 25-30% in urban areas and 15-20% in rural areas. The World
Health Organization reports (22) that more than 50% of coronary artery disease and
more than 40 lakh deaths/year are due to dyslipidemia 80% of lipid disorders are
related to food and sedentary life style and 20 % of lipid disorders are familial
disorders (23).
RISK FACTORS FOR DYSLIPIDEMIA:
1.   Obesity,
2.   Physical inactivity,
3.   Alcohol intake,
4.   Smoking,
5.   Diet rich in fats.
TYPES OF LIPOPROTEINS:
1. CHYLOMICRONS
2. VERY LOW DENSITY LIPOPROTEIN (VLDL)
3. LOW DENSITY LIPOPROTEIN (LDL)
4. HIGH DENSITY LIPOPROTEIN (HDL)
5. FREE FATTY ACID (FFA)
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CHYLOMICRONS:
• They are formed in intestinal mucosa and rich in triglycerides
• They mainly contain apo B-48.
• They are metabolised  mainly by lipoprotein lipase (LpL) in the endothelial
cells
• Lipoprotein lipase (LpL)  converts triglycerides into glycerol and free fatty
acids
• Insulin increases the lipoprotein lipase (LpL) activity.
VERY LOWDENSITY LIPOPROTEIN(VLDL):
• It is formed in liver and contains hepatic cholesterol, apo B-100,C II and apo E.
• It carries endogenous triglycerides from liver to peripheral tissues and then gets
converted to LDL cholesterol which is again taken up by LDL receptor present
in liver .
LOW DENSITY LIPOPROTEIN(LDL):
• It transport cholesterol from liver to peripheral tissues which are derived from
VLDL cholesterol
• It contains mainly apo B100 lipoprotein and it is also called as bad cholesterol .
• Serum LDL level directly correlates with cardiovascular disorders.
• Elevated LDL cholesterol infiltrates through arterial wall and  is taken up by
macrophages which is the initial event of atheroscelerosis.
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LIPOPROTEIN(a):
• It ia an oxidized and glycated LDL ,containing only apo B-100 and is
increased in   smokers and diabetes.
• it is also called as little rascal and has homology with plasminogen .
• it  interferes with fibrinolysis.
• people with Lp(a) more than 30mg/dl has an increased risk for developing
MI/stroke at younger age groups
• Indian people have higher level of Lp (a) than western people.
HIGH DENSITY LIPOPROTEIN (HDL):
• It transports cholesterol from peripheries to the liver.
• It contains apo-A1 and  apo-A2 and C ,E.
• The level of HDL in serum is inversely related to the development of
MI / stroke, hence it is called as good cholesterol.
CAUSES FOR DYSLIPDEMIA:
ELEVATED LDL CHOLESTEROL:
• Nephrotic syndrome
• Hypothyroidism
• Anorexia nervosa
• Cholestasis
• Hepatoma
• Acute intermittent porphyria
• Drugs like thiazide diuretics,cyclosporine ,carbamazepine
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REDUCED LDL CHOLESTEROL:
• Liver disease
• Malabsorption
• Chronic infection
• Hyperthyroidism
• Drugs like niacin toxicity
ELEVATED HDL CHOLESTEROL:
• Alcohol
• Exercise
• Drugs like estrogen
REDUCED HDL CHOLESTEROL:
• Smoking
• Obesity
• Type 2 diabetes mellitus
• Malnutrition
• Drugs like anabolic steroids and selective beta blockers.
ELEVATED VLDL CHOLESTEROL:
• Hepatitis
• Obesity
• Glycogen storage disorders
• Alcohol
18
• Renal failure
• Sepsis
• lipodystrophy
• Cushing’s syndrome,acromegaly
• Pregnancy
• Drugs like retinoic acid
ELEVATED IDL CHOLESTEROL:
• Multiple myeloma
• Monoclonal gammopathy
• Hypothyroidism
ELEVATED LIPOPROTEIN(a)
• Chronic  renal failure
• Drugs like growth hormone,isotretinoin
• Menopause
• Acromegaly
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ELEVATED CHYLOMICRONS:
Auto immune disease
Diabetes Mellitus
APOLIPOPROTEINS:
APOPROTEIN COMPONENT FUNCTIONS
apo A-1 HDL -2
Activation of lecithin-
cholesterol acyl
transferase
apo A-II HDL-3
Inhibits  lecithin-
cholesterol acyl
transferase
apo B -100 LDL,VLDL Binds LDL receptor
apo B-48 CHYLOMICRONS 48% size of B-100%
apo C –I CHYLOMICRONS,VLDL
Activation of lecithin-
cholesterol acyl
transferase
apo C-II CHYLOMICRONS,VLDL
Activates extrahepatic
lipoprotein lipase in
vessel wall
apo C –III CHYLOMICRONS,VLDL
Inhibits lipoprotein
lipase
Apo E LDL,VLDL,CHYLOMICRON
Ligand for hepatic
uptake
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DESIRED LDL CHOLESTEROL GOALS:
LDL cholesterol lowering is the best way to reduce the cardio vascular risk.
The desired level of LDL cholesterol is determined  by  independent  risk factors and
their framingham 10 year risk score for developing cardiovascular disorder (24).
INDEPENDENT RISK FACTORS :
• High LDL Cholesterol
• Polycystic Ovary Syndrome
• Smoking
• Hypertension
• Low HDL Cholesterol(40mg/dl)
• Family History Of Coronary Artery Disease
 In male first degree relative younger than 55 years
 In female first degree relative younger than 65 years
• Evidence of coronary artery calcification and age (male ≥45 years and females
≥ 55 Years)
 Chronic renal disease stage ¾(CKD)
RISK CATEGORY:
EXTREME RISK:
 History of premature Atherosclerotic cardiovascular disease(ASCVD)
PROGRESSIVE ASCVD AFTER achieving an LDL cholesterol<70mg/dl
Established CAD in diabetic, CKD patients
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TREATMENT GOALS:
 LDL-CHOLESTEROL - <55mg/dl
 NON-HDL CHOLESTEROL - <80mg/dl
 Apo B -<70mg/dl
VERY HIGH RISK GROUP:
 Established /Recent Hospitalization For ACS
 Framingham 10 Year Risk Score >20%
 Diabetes/CKD With More Than 1 Risk Factors
TREATMENT GOALS:
 LDL-CHOLESTEROL - <70mg/dl
 NON-HDL CHOLESTEROL - <100mg/dl
 Apo B -<80mg/dl
HIGH RISK GROUP:
 More Than 2 Risk Factors
 Framingham 10 Year Risk 20%
 Diabetes /CKD Stage ¾ With No Risk Factors
TREATMENT GOALS:
 LDL-CHOLESTEROL - <100mg/dl
 NON-HDL CHOLESTEROL - <130mg/dl
 Apo B -<90mg/dl
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MODERATE RISK:
<2 Risk factors and FRAMINGHAM 10 Year Risk <10%
TREATMENT GOALS:
LDL-CHOLESTEROL - <100mg/dl
NON-HDL CHOLESTEROL - <130mg/dl
Apo B -<90mg/dl
LOW RISK:
No Risk Factors
TREATMENT GOALS:
 LDL-CHOLESTEROL - <130mg/dl
 NON-HDL CHOLESTEROL - <160mg/dl
 Apo B –not recommended
DRUGS USED TO TREAT ELEVATED LDL CHOLESTEROL:
Statins are the important group of drugs used in the management of
dyslipidemia to lower the LDL cholesterol. Multiple studies conducted across the
world shows the role of statins in LDL cholesterol reduction and prevention of
development of cardio vascular  disease. Statins  inhibits the HMG-CoA Reductase
enzyme which is the rate limiting  key enzyme in the cholesterol synthesis , leading to
increased hepatic LDL receptor activity and increased hepatic uptake of circulating
LDL cholesterol and reduction in serum LDL cholesterol.
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In a study conducted by Nissen et al(25) on intensive Vs moderate  lipid
lowering on progression of coronary atherosclerosis , intensive lipid lowering with
Atorvastatin 80 mg per day (-0.4%) and decreased the progression of  coronary
atherosclerosis compared to the patient who received pravastatin 40mg per day(2.7%).
In this trial they also found  more reduction of inflammatory marker like C-reactive
protein(CRP) in patient who received Atorvastatin (36.4%) than with pravastatin
(5.2%). MEGA trial conducted by Nakamura et al(26) on primary prevention of CVD
with pravastatin in japan shows that coronary artery disease was lowered in diet  plus
Pravastatin  group ( 66 events) compared to the diet alone groups (101events). Mean
total cholesterol was decreased by 11.5% in statin plus diet group compared to 2.1%
in diet group.LDL cholesterol reduction was 18.0%in statin plus diet group compared
to 3.2%in diet alone group.
NON STATIN PHARMACOLOGICAL TREATMENT FOR DYSLIPIDEMIA:
Hypertriglyceridemia and low HDL  are  important part of dyslipidemia. Both
are individual predictors  of cardiovascular risk in metabolic syndrome. If  fasting
serum triglyceride is more than 150mg% patient is said to have elevated
triglycerides.VA-HIT trial(27) conducted by robins et al on relation of gemfibrozil
treatment and lipid levels on major coronary events found that every 5 mg/dl raise in
HDL cholesterol with gemfibrozil treatment resulted in 11% reduction in cardio
vascular events .
24
LDL CHOLESTEROL LOWERING DRUGS:
DRUG INITIAL DOSE MAXIMAL DOSE
HMG CoA REDUCTASE INHIBITOR
LOVASTATIN 20-40mg/day 80mg/day
ATORVASTATIN 20-40mg/day 80mg/day
SIMVASTATIN 20-40mg/day 80mg/day
ROSUVASTATIN 5-20mg/day 40mg/day
PITAVASTATIN 1mg/day 4mg/day
PRAVASTATIN 40-80mg/day 80mg/day
FLUVASTATIN 20-40mg/day 80mg/day
BILE ACID SEQUESTRANTS
CHOLESTYRAMINE 4g/day 32g/day
COLESTIPOL 5g/day 40g/day
COLESELVAM 3750mg/day 4375mg/day
25
DRUGS FOR ELEVATED TRIGLYCERIDES:
DRUGS INITIAL DOSE MAXIMAL DOSE
FIBRIC ACID DERIVATIVES
GEMFIBROZIL 600mg/bid 600mg/bid
FENOFIBRATE 145mg qd 145mg qd
OMEGA-3 FATTY
ACIDS
4g /day 4g/day
NICOTINIC ACID DERIVATIVES
IMMEDIATE RELEASE 100mg tid 1g  tid
SUSTAINED RELEASE 250mg tid 1.5 g bid
EXTENDED RELEASE 500mg qhs 2g qhs
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METABOLIC SYNDROME AND CARDIOVASCULAR RISK:
Metabolic Syndrome is a strong independent risk factor for
cardiovascular risk. Various inflammatory markers plays a significant role in
development of cardiovascular disease in Metabolic Syndrome. A  study by lakka HM
et al(28) on metabolic syndrome and cardiovascular risk in middle aged men,observed
that men with Metabolic Syndrome were 2.9times at  increased risk of developing
cardiovascular disease than those without  metabolic syndrome.
Abdominal Obesity plays the main role in Metabolic Syndrome and had
positive correlation with insulin resistance and triglyceride and negative correlation
with HDL cholesterol level. In Metabolic Syndrome patients myocardial oxygen
demand and sympathetic activity is increased, which will cause micro vascular
dysfunction leading to coronary artery disease.
27
RELATIONSHIP BETWEEN METABOLIC SYNDROME COMPONENTS AND
CARDIOVASCULAR RISK:
LOWER
HDL
HIGHER
TGL
PROTHROMBOTIC
STATE
PROINFLAMMATORY
STATE
CORONARY ARTERY DISEASE
ATHEROSCELEROSIS
HIGHER
apo B HIGHER
BP
HIGH
GLUCOSE
LOWER
HDL
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INFLAMMATORY MARKERS AND METABOLIC SYNDROME:
Inflammatory markers plays pivotal role in the development of metabolic
syndrome and cardiovascular disease.  Inflammation is the bridging marker between
metabolic syndrome and atherosclerosis. Chronic low grade inflammation was most
commonly associated with insulin resistance and endothelial dysfunction.
The inflammatory markers are
1.   Adhesion molecules,
2.   Cytokines,
3.  Fibrinogen,
4.  C- reactive protein(CRP),
5.  White blood cell count,
6.  Erythrocyte sedimentation rate.
Microalbuminuria  which is a  urinary marker of systemic Inflammation is
elevated in Metabolic Syndrome. Adipose tissue is the important site where most of
the above pro inflammatory cytokines like leptin , resistin, interlukin 6 , C reactive
protein, TNF alpha  and  adipokines are secreted which will produce insulin
resistance, endothelial dysfunction and atherosclerosis.
C REACTIVE PROTEIN AND METABOLIC SYNDROME:
It is a pentameric protein found in plasma whose levels rise in response to
inflammation .It is an acute phase reactant secreted from  hepatocytes  in response to
factors released from adipocytes  and macrophages. Half life of CRP is 4-7 hours.
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CRP elicits pro atherogenic and pro-inflammatory effects and produces
endothelial dysfunction. It decreases nitric oxide release and inhibits angiogenesis,
and stimulates endothelial cell apoptosis. It also causes increased basal reactive
oxygen species production in vascular smooth muscle cells and up regulates the AT-
1(angiotensin 1) receptor vascular smooth muscle cells . A study from cuttack in
2012(29) observed  that Indian population with type 2 diabetes with or without
macrovascular disease had higher hs-CRP compared to healthy subjects. All
components of the  metabolic syndrome are significantly associated with elevated
CRP. In a study by prakash kikkeri gowdaiah (30), patients with metabolic syndrome
had  higher mean value of  hs-CRP(8.3±SD 1.04) than patients without metabolic
syndrome(1.6± SD 0.79).
C REACTIVE PROTEIN AND CARDIAC RISK
CARDIAC RISK
hs-C REACTIVE
PROTEIN (mg/L)
LOW
<1.0
AVERAGE 1.0-3.0
HIGH
>3.0
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TOTAL WHITE BLOOD CELL COUNT(WBC) AND METABOLIC
SYNDROME:
Total WBC COUNT is one of the readily available and cost effective method
for detection of underlying  systemic inflammation . A study by shim WS et al
(31)found that total WBC count increases as the number of components of metabolic
syndrome increases.  WBC count was positively correlated with waist circumference,
systolic blood pressur , diastolic blood pressure , triglycerides.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE(COPD):
COPD is characterized by obstruction to the airflow , that is not fully reversible
and there is no other explanation for the obstruction. it is due to the abnormal
inflammatory response to noxious particles/gas by lungs.
DISEASE BURDEN OF COPD:
According to projections of global mortality and burden of disease from 2002
to 2030 (32)it is estimated that COPD will be the fourth leading cause of death
globally in 2030,which was fifth leading cause of death in 2002.WHO in December
2017(33) report  quotes that the  incidence of COPD is likely to increase in coming
years due to the higher prevalence of smoking and aging in many counties in the
world. It is not a curable disease but treatment of disease will relieve the symptoms
and improve the quality of life and reduce the risk of death.
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SPECTRUM OF COPD:
 Chronic bronchitis
 Emphysema
 Bronchial asthma
 Bronchiectasis
 Small airway disease,bronchiolitis
FACTORS RESPONSIBLE FOR COPD:
ENVIRONMENTAL FACTORS:
 Smoking
 Indoor air pollution
 Occupation
 Low socioeconomic status
HOST BASED FACTORS:
 Genetic factors
 Airway hyper reactivity
32
CHRONIC INJURY LIKE SMOKING
PICTURE REPRESENTING OVERLAP BETWEEN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
EMPHYSEMA
ALVEOLAR WALL
DESTRUCTION
BRONCHIAL   HYPERRESPONSIVENESS
SMALL AIRWAY DISEASE
CHRONIC BRONCHITIS
AIRWAY INFLAMMATION
ASTHMA
REVERSIBLE OBSTRUCTION
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SMOKING AND COPD:
Across the world, smoking is one of the important risk Factor  in the
development of COPD. On long term outcomes in mild/moderate COPD in the
European community respiratory health survey(34), smoking was the most important
risk factor associated with COPD. Women are most likely to develop lung disease
from smoking than men as they show lung function reduction in association with less
total exposure.
In An article by Rafael laniado(35) on smoking and COPD, life long smokers
will have a 50% Chance of developing COPD during their life span, while rate of
progression of COPD Will be decreased in the smokers who are all at risk of
developing COPD who has stopped Smoking.
COPD AND INDOOR AIR POLLUTION:
Burning solid fuels like wood  and animal dung for cooking is a common
practice all over the world particularly in developing countries. This will result in
exposing the women and children to the smoke containing  respirable particles and
putting them at risk for developing COPD and also increases the risk of COPD in
smokers. The WHO has predicted that  approximately one million people/year die of
COPD due to indoor air pollution.
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OCCUPATION:
According to American thoracic society(36)15% COPD is due to occupational
exposure.. Exposure to organic and  inorganic dusts are the risk factors contributing to
the development of COPD, also  persons involved in construction  work and  plastic
manufacturing  are at  increased risk of developing COPD. Smoking may be a
confounding factor which will increase the chance of  developing COPD in these
workers .In a review article by blanc PD et al on occupation and COPD, population
attributable risk is minimum 15% in occupation related COPD patients(37).
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PATHOPHYSIOLOGY OF COPD FROM SMOKING:
;
CIGARETTE SMOKE AND HOST FACTORS
ACTIVATED MACROPHAGES RELASES
CHEMOATTRACTANTS LIKE LEUKOTRINES B4 and
INTERLUKIN 8 LEADING TO NEUTROPHIL ACTIVATION
INCREASED OXIDANTS AND FREE RADICAL
PRODUCTION
ACTIVATES PROTEASES
LIKE CATHEPSINS
,MATRIX
METALLOPROTEINASES
EPITHELIAL CELL
AND
MATRIXINJURY
INCREASED
MUCUS
PRODUCTION
CHRONIC
BRONCHITIS
EMPHYSEMA
COPD
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SOCIO ECONOMIC STATUS AND COPD:
People with low socio economic status are increased risk of Developing  COPD
than high socio economic class people  because these people are more likely to get
repeated lower respiratory tract infections due to over crowding , poor access to
medical facility ,increased exposure to house hold allergens, and increased amount of
smoking.
GENETIC FACTORS AND COPD :
Alpha-1 antitrypsin (AAT) deficiency is one of the important
genetic factor  implicated  in the development of COPD in younger age group. Single
nucleotide polymorphisms(SNP’s) of matrix metalloproteinases(MMPS) and tissue
inhibitors of matrix metalloproteinases (TIMP) had been studied in relation with
COPD and emphysema. Matrix metalloproteinase degrades  collagen and alpha-1
antitrypsin and activates tumour necrosis factor. Hirano et al(38) demonstrated that
SNP’s of the TIMP 2 gene have been linked to COPD in Japanese population .Other
possible genetic variations that may be associated with development of COPD that is
yet to be proved by large genome wide studies are
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GENE SYMBOL FUNCTIONALCATEGORY LOCUS
SERPINA 1 ANTIPROTEASE 14q32
MMP 12 PROTEASE 11q22
MMP 1 PROTEASE 11q22
SOD 3 ANTIOXIDANT 4p15
GSTM 1 DETOXIFYING 1p13
TGFB 1 CYTOKINE 19q13
CHRONIC BRONCHITIS:
It is defined as persistent productive cough for at least three consecutive
months in at least two consecutive years without any identifiable
cause.Microscopically it consists of goblet cell hyperplasia , bronchiolar wall fibrosis,
chronic inflammation.
PATHOPHYSIOLOGY:
1.MUCUS HYPERSECRETION:
Hyper secretion of mucus is the earliest feature of chronic bronchitis associated
with hypertrophy of the sub mucosal glands.
2.INFLAMMATION:
Inhaled smoke produces  both acute and chronic inflammatory response and
fibrosis of the  small airways leading to chronic obstructive pulmonary disease .
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3.INFECTION :
It does not initiate chronic bronchitis but produce acute Exacerbations .
EMPHYSEMA:
It is characterized by permanent enlargement of air spaces(39) distal to the
terminal bronchioles. Microscopic appearance consists of abnormally large alveoli
separated with focal centriacinar fibrosis.
FOUR MAJOR TYPES OF EMPHYSEMA INCLUDES:
1 Centriacinar emphysema - Most common form (>95% cases)
2. Panacinar emphysema - Mostly associated with alpha-1 antitrypsin deficiency
3. Paraseptal emphysema - Associated most commonly with spontaneous
pneumothorax
4.  Irregular - Clinically insignificant type of emphysema.
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PATHOGENESIS OF EMPHYSEMA:
WHEN TO SUSPECT COPD AND PERFORM SPIROMETRY?(40)
If persons aged above  40 years presents  with any of the following features we
should suspect COPD and consider  doing  Spirometry ,  It includes
1.DYSPNEA- - Persistent, Increasing over time,
Worsens with exercise.
2.CHRONIC COUGH- - May be unproductive and intermittent with
Recurrent wheeze
3.CHRONIC SPUTUM PRODUCTION
4.RECURRENT LOWER RESPIRATORY TRACT INFECTIONS
5.HISTORY OF RISK FACTORS- Host factors like genetic factors /developmental
abnormalities
Tobacco smoke
Smoke from cooking and burning fuels and
Woods,
Occupational dusts, vapors, fumes and gases
SMOKING /AIR
POLLUTANT+
GENETIC
PREDISPOSITION
OXIDATIVE STRESS,
INCREASED APOPTOSIS
INFLAMMATORY
CELLS,RELEASE OF
INFLAMMATORY
MEDIATORS
PROTEASE,
ANTIPROTEASE
IMBALANCE
ALVEOLAR WALL
DESTRUCTION
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6.FAMILY HISTORY OF COPD/ CHILDHOOD FACTORS
DIFFERENCE BETWEEN EMPHYSEMA AND CHRONIC BRONCHITIS
CHRONIC
BRONCHITIS
EMPHYSEMA
AGE 40-45 YEARS 50-75 YEARS
DYSPNEA MILD/LATE STAGE SEVERE/EARLY ONSET
COUGH EARLY LATE
SPUTUM COPIUS SPUTUM SCANTY SPUTUM
INFECTION COMMON OCCASIONAL
CORPULMONALE COMMON RARE /TERMINAL
AIRWAY RESISTENCE INCREASED NORMAL/SLIGHTLY INCREASED
ELASTIC RECOIL NORMAL LOW
XRAY CHEST PROMINENT VESSELSLARGE HEART
HYPERINFLATION
SMALL HEART
APPEARANCE BLUE BLOATERS PINK PUFFERS
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LUNG VOLUMES:
TIDAL VOLUME:
Amount of air that is inspired or expired in one quite breathing
Normal value: 500ml
INSPIRATORY RESERVE VOLUME (IRV):
Amount of air that can be inhaled in excess of tidal inspiration with  maximum
effort is called inspiratory reserve volume
Normal value: 3000 ml
EXPIRATORY RESERVE VOLUME (ERV):
Amount of air that can be exhaled in excess of tidal inspiration with maximum
effort is called inspiratory reserve volume
Normal value: 1200 ml.
RESIDUAL VOLUME (RV):
Amount of air remaining in the lungs after forceful expiration is called residual
volume
Normal Value: 1200 ml
LUNG CAPACITIES:
VITAL CAPACITY (VC):
Amount of air that can be exhaled with maximum effort after forceful
inspiration . VC =TV+ERV+IRV (500+1200+3000) =4700 ml
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INSPIRATORY CAPACITY (IC):
Maximum amount of air that can be inhaled after normal tidal inspiration.
IC=TV+IRV (500+3000) =3500 ml.
FUNCTIONAL RESIDUAL CAPACITY (FRC):
Amount of air remaining in the lungs after a normal tidal Expiration .
FRC=RV+ERV (1200+1200) = 2400ml.
TOTAL LUNG CAPACITY (TLC):
Maximum amount of air the lungs can contain is called total lung
capacity.TLC=RV+VC(1200+4700)=5900ml
FORCED VITAL CAPACITY (FVC):
The maximum amount of air that can be expired after a maximal inspiratory
effort is called as a forced vital capacity which is used clinically as a measure of
pulmonary function .The fraction of vital capacity of air that is exhaled during  the
first second of the forced expiration is called as forced expiratory volume1 (FEV1) .
SPIROMETRY: Spirometry  is the objective measurement of airflow limitation.
POINTS TO REMEMBER WHILE DOING SPIROMETRY:
PREPARATION:
1. The supervisor needs training in quality performance and technique
2. Maximal patient effort is needed to avoid underestimation of values
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DRUGS USED FOR BRONCHODILATATION:
1. 400 micrograms of short acting beta 2 agonist – FEV1 should be measured
after 10-15 minutes.
2. 160 micrograms of short acting anti cholinergics – FEV1 should be measured
after 30-45 minutes.
PERFORMANCE:
1. The pause between inspiration and expiration should be less than one second
2. The recording should go on long enough for a volume plateau to be reached
3. FEV1 and FVC is the largest value obtained from any of the 3 technically correct
curves
4. Presence of post bronchodilator FEV1/FVC<0.7 confirms the airflow obstruction.
SPIROMETRY FINDINGS IN OBSTRUCTIVE LUNG DISEASE:
1. FEV1/FVC ratio <0.70
2. FEV1< 80% predicted
3.FEV 25-75%  <60% predicted
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FOLLOWING GRAPH COMPARES NORMAL VERSUS OBSTRUCTIVE
FLOW VOLUME CURVE
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THE FOLLOWING GRAPH COMPARES NORMAL VERSUS
OBSTRUCTIVE VOLUME TRACE
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RESTRICTIVE LUNG DISEASE FINDINGS IN SPIROMETRY:
1. FEV1/FVC ≥ 0.8
2. FVC < 80% predicted
FOLLOWING GRAPH COMPARES NORMAL VERSUS RESTRICTIVE
FLOW VOLUME CURVE
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GLOBAL INITIATIVE FOR OBSTRUCTIVE LUNG DISEASE (GOLD)
STAGING FOR SEVERITY OF COPD (40).
STAGE SEVERITY POST BRONCHODILATOR FEV1
1 MILD FEV1≥ 80% PREDICTED
2 MODERATE 50%≥FEV1<80% PREDICTED
3 SEVERE 30%≥FEV1<50% PREDICTED
4 VERY SEVERE FEV1<30% PREDICTED
CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METABOLIC
SYNDROME :
It is estimated that the approximately 5.91 million and 16.3 million people in
urban  and rural areas are suffering from COPD respectively(41)and approximately
one- third of the urban Indian  population are estimated to  have Metabolic Syndrome .
Metabolic Syndrome prevalence is  twice common in COPD patients compared to
general population .several studies conducted across the world and India has found out
the prevalence to be  between 25.6 to 60.9 %(42) ,(43) .
PATHOGENESIS OF METABOLIC SYNDROME IN COPD PATIENTS(44) :
Metabolic syndrome in COPD patients is of multi-factorial Origin and factors
which link these two diseases are smoking , physical inactivity and Obesity. A study
from france (45) has shown that systemic inflammatory response in smoker is
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responsible for COPD and metabolic syndrome. The Guangzhou bio bank study
(46)shown that central obesity is the important factor responsible for airway
obstruction and also found that metabolic syndrome is more common in people who
are having significant airway obstruction. Mechanism by which airflow limitation
occurs in central obesity includes reduced lung compliance, increased work of
breathing , and small airway dysfunction. Possible mechanisms that links these two
diseases are steroid use, visceral fat inflammation, physical inactivity, hypogonadism .
Low grade inflammation is the important mechanism in development
of Metabolic Syndrome in COPD patients.
SYSTEMIC INFLAMMATION AND COPD(44) :
Adipose tissue  hypoxia due to poor oxygenation because of  poor neo –
vascularization ,reduced blood supply to adipose tissue in obese COPD patients leads
to increased production of pro inflammatory adipokines and leptins which predisposes
to insulin resistance and metabolic syndrome in COPD patients.
HYPOGONADISM IN COPD AND METABOLIC SYNDROME :
Hypoxia and steroid therapy in COPD patients will lead to low testosterone
levels and hypogonadism . several studies shown that hypogonadal  men are at risk of
developing metabolic syndrome(47) .So low testosterone levels is one of the important
risk factor for development of Metabolic Syndrome in COPD patients.
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MECHANISM OF DEVELOPMENT OF METABOLIC SYNDROME IN
COPD PATIENTS(44):
COPD
SMOKING,
POLLUTION,
GENETIC FACTORS
PHYSICALINACTIVITY,
SEDENTARY LIFE
STYLE
SYSTEMIC
INFLAMMATION
ADIPOSE
TISSUEHYPOXIA,
ADIPOKINES
SECRETION
METABOLIC
SYNDROME
INCREASED CARDIO
VASCULAR
MORTALITY
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PHYSICAL INACTIVITY IN COPD AND METABOLIC SYNDROME (44):
Physical inactivity increases as the severity of the COPD increases  which will
lead to central obesity and adipose tissue inflammation and insulin resistance . This in
turn leads to development of metabolic syndrome. A study by watz et al (43)clearly
shows  the link between metabolic syndrome and COPD patients.
EFFECTS OF STEROIDS IN COPD AND METABOLIC SYNDROME:
Abdominal obesity, Impaired Glucose tolerance, Hypertension and
Dyslipidemia are the known complications of steroid use and these components are
part of the Metabolic Syndrome. As COPD patients are more frequently exposed to
the steroids , which is the drug of choice in treating  acute exacerbations they
ultimately land up in developing Metabolic Syndrome.
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OBJECTIVES:
PRIMARY OBJECTIVE:
To determine  the prevalence of Metabolic syndrome in  Chronic Obstructive
Pulmonary Disease .
SECONDARY OBJECTIVE:
1. To study the Association of systemic inflammatory markers like C-reactive
protein[CRP] and Total white blood cell  Count in patients with and without
metabolic syndrome
2. To study the prevalence of metabolic syndrome in various Stages of  chronic
obstructive pulmonary disease.
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METERIALS AND METHODS
STUDY DESIGN: This study is a cross sectional study .
STUDY PERIOD : October 2017 to September 2018
STUDY POPULATION: This study was conducted among 100 COPD patients who
attended Thoracic Medicine outpatient department in Government Vellore Medical
College & Hospital.
INCLUSION CRITERIA:
Patients more than 40 years of age diagnosed as COPD based on Global
initiative for chronic obstructive pulmonary disease (GOLD) guidelines, history,
clinical examination, and pulmonary function test and without exacerbations are
included in the study.
EXCLUSION CRITERIA:
1. Patients  denying consent .
2. Presence of asthma or other chronic respiratory diseases.
3. Presence of malignancy or serious comorbidities that prevents the study
completion.
4. Patients with active pulmonary tuberculosis
5. Patients with acute exacerbation of COPD and/or use of systemic
corticosteroids  in the  preceding 3 months.
6. Patients with known cardio vascular diseases
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COLLABORATING DEPARTMENTS:
Department of thoracic medicine
Department of biochemistry
The participating patients were given detailed information about the study and
then their willingness to participate in the study was confirmed and then informed
consent was obtained from the patients. Following which detailed history and
examination was done in the patients and patients who were meeting the inclusion
criteria and does not fit in any exclusion criteria were selected and allowed to
participate in the study.
Totally 100 COPD patients were included in the study. Detailed history
regarding occupation , income ,smoking, diabetes ,hypertension ,   recent exacerbation
were asked in detail. Anthropometric measurements like weight, height were
measured . chest x ray and electrocardiogram was taken for  all the patients.
Patients socio economic status was assessed and they were classified according
to the modified kuppuswamy scale(48) .Patients who smoked more than 100 cigarettes
in their lifetime was considered as a smoker
After eliciting detailed history ,all the patients underwent spirometry procedure
before and after  bronchodilator therapy and classified according to the GOLD
guidelines.
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MEASUREMENTS IN OUR STUDY:
WAIST CIRCUMFERENCE:
It is measured halfway between the costal margin and iliac crest and at the end
of second expiration, waist circumference was  measured
HIP CIRCUMFERENCE:
It was measured using inch tape which was kept parallel to the floor in the
widest part  of the buttocks with  patient wearing little clothing.   Using waist and hip
circumference waist hip ratio was measured and  body mass index (BMI) was
measured using the following formula :
Body mass index (BMI)= patient weight ( kilogram) / height ²(metres)
OBESE:
Patient was said to be obese if they had hip circumference of >80 cm in
females  and >90 cm in males or body mass index of ≥25kg/m² or waist hip ratio of ≥
0.85 in  females and ≥0.90 in  males.
BLOOD PRESSURE (BP):
BP was measured after 30 minutes of rest, in sitting posture and arm at the
level of heart .patient was advised to abstain from caffeine and smoking six hours
before the BP measurement. The BP was once again measured after 24 hours and
average of the two readings were taken.
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LAB INVESTIGATIONS:
1. Haemoglobin
2. Total count
3. C-Reactive protein
4. Fasting blood sugar
5. Fasting lipid profile- Total Cholesterol, Triglycerides, HDL Cholesterol
BLOOD COLLECTION METHODS:
After an overnight fasting for twelve hours, venous blood sample was collected
for fasting blood glucose, total WBC count, CRP, Total Cholesterol, Triglycerides,
HDL Cholesterol. Enzyme calorimetric method was used to measure the Total
Cholesterol , Triglyceride,  HDL cholesterol.
VLDL cholesterol is measured from triglycerides (VLDL
holesterol=triglycerides/5) Friedewald formula (FF)(49) was used to measure LDL
cholesterol. LDL cholesterol = total cholesterol-HDL cholesterol-VLDL
cholesterol. Metabolic Syndrome was diagnosed if three out of the five components
was present according to the Modified NCEP ATP III guidelines.
In our study, patient was said to have positive  C Reactive Protein if the
specimen was agglutinated in 1:2 dilution (≥12 mg / litre non diluted specimen),those
who’s specimen does not get agglutinated in 1:2 dilution ,then it was considered
negative.
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SPSS16 software was used for statistical analysis. P value Of <0.05 was taken
as significant value. Influence of various factors on Metabolic Syndrome in COPD
patients is studied and statistical significance between various factors was studied with
the help of chi – square test . ANOVA is used to analyse the effect of multiple factors
on Metabolic Syndrome in COPD patients.
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RESULTS:
In our study , the study population predominantly consisted  of male patients
because of the important risk factor smoking, it is most common among males than
females hence the disease  COPD is more in males compared to females .
GENDER NO OF COPD PATIENTS
MALE 82
FEMALE 18
There is no statistically significant difference in gender distribution of COPD patients
18
GENDER DISTRIBUTION
82
MALE-82%
FEMALE -18%
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BASE LINE CHARACTERISTICS OF COPD PATIENTS IN OUR STUDY:
Variable Total Minimum Maximum Mean
Standard
deviation
AGE(years) 100 41 75 61.20 7.877
HEIGHT(cm) 100 146 178 162.76 6.425
WEIGHT(kg) 100 50 88 65.49 7.720
BMI(kg/m²) 100 19.720 33.200 24.76435 2.705947
WC(cm) 100 76 116 89.73 8.478
HC(cm) 100 81 120 95.20 8.138
WHR 100 0.8148 1.0943 0.942892
0.0440758
In our study, minimum age of the patients is 41 years and maximum age is 75 years
The mean BMI and waist circumference  in  our  study  is 24.76± SD 2.70(kg/m²) and
89.73± SD 8.478(cm). In our study minimum height and weight of the patients are
146 cm and 50 kg and maximum height and weight are 178 cm and 88 kg
respectively. .Mean Waist Hip ratio in our study is 0.942892± SD 0.0440758 .
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VARIABLE TOTAL MINIMUM MAXIMUM MEAN STANDARDDEVIATION
SBP(mmHg) 100 106 164 131.29 14.451
DBP(mmHg) 100 68 102 83.64 8.102
FASTING
GLUCOSE
(mg/dl)
100 69 128 99.56 11.735
TOTAL
CHOLESTEROL
(Mg/dl)
100 88 265 160.64 36.271
HDL
CHOLETEROL
(mg/dl)
100 28 59 40.92 5.590
LDL
CHOLESTERL
(mg/dl) 100
17 176 88.55 35.530
TRIGLYCERIDES
(mg/dl) 100 101 254 158.19 29.984
VLDL
CHOLESTEROL
(mg/dl)
100 20.2 50.8 31.638 5.99647
TOTALWBC
COUNT
(Cells /cu mm)
100 3100 13300 7195 2546.353
In our study mean systolic and diastolic blood pressure is 131.29± SD 14.451
mmHg and 83.64± SD 8.102 mm Hg respectively. Minimum and maximum blood
glucose values is 69 and 128 mg/dl respectively and Mean Fasting
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Glucose is 99.56 ± SD11.735 mg/dl. Minimum and Maximum Total
cholesterol and Triglycerides levels is 88 and 265 mg/dl and 101 and 254 mg/dl
respectively. Mean HDL, LDL and VLDL cholesterol level in our population are
40.92,88.55 and 31.638 mg/dl  respectively. Total WBC count in our study population
was 7195 cells /cu mm and Minimum and Maximum values of 3100 and 13300
cells/cu mm  .
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DISTRIBUTION OF COPD PATIENTS ACCORDING TO GOLD SEVERITY
CLASSIFICATION
GOLD STAGING SEVERITY NO OF COPD PATIENTS
STAGE 1 MILD 15
STAGE 2 MODERATE 56
STAGE 3 SEVERE 22
STAGE 4 VERY SEVERE 7
TOTAL 100
In our study maximum number of patients are from stage two and three
consisting  78% study population , stage 1 and stage 4 COPD patients  is  15% and 7%
respectively.
22
NO OF PATIENTS IN DIFFERENT STAGING OF
COPD
15
56
7
STAGE 1
STAGE 2
STAGE 3
STAGE 4
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PREVALENCE OF METABOLIC SYNDROME IN COPD PATIENTS:
In our study population Metabolic Syndrome was prevalent in 46% of COPD
patients which indicates that three or more components of Metabolic Syndrome were
present in these patients.
46
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METABOLIC SYNDROME PREVALENCE
METABOLIC SYNDROME - YES
METABOLIC SYNDROME - NO
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DISTRIBUTION  OF METABOLIC SYNDROME COMPONENTS IN COPD
PATIENTS
NO OF
COMPONENTS NO OF COPD PATIENTS
0 7
1 15
2 32
3 26
4 19
5 1
In our study only one patient had all five components of Metabolic Syndrome
where as Seven patients does  not have any components of Metabolic Syndrome.15
patients had Only  one component and 32 patients had two components  of the
Metabolic Syndrome.These 47 patients who  had one or two components of the
Metabolic Syndrome may develop Metabolic Syndrome in near future and  have
increased risk of developing cardio vascular disease  . Hence screening for metabolic
syndrome is needed in these patients .
7
15
32
26
19
1
NO OF COPD PATIENTS
0' COMPONENT
1' COMPONENT
2' COMPONENTS
3' COMPONENTS
4'COMPONENTS
5' COMPONENTS
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PREVALENCE OF METABOLIC SYNDROME IN DIFFERENT COPD
STAGES :
GOLD STAGING METABOLICSYNDROME -YES
METABOLIC
SYNDROME-NO TOTAL
STAGE 1 3 (20%) 12 (80%) 15
STAGE 2 30 (53.6%) 26 (46.4%) 56
STAGE 3 12 (54.5%) 10 (45.5%) 22
STAGE 4 1  (14.3%) 6 (85.7%) 07
TOTAL 46 (46%) 54 (54%) 100
There is statistically significant difference  between
prevalence of Metabolic Syndrome in different COPD stages with p value 0.031.
The prevalence of Metabolic Syndrome was 20% , 53.6%, 54.5%,14.3% in stage 1,
stage 2, stage 3 and stage 4 COPD respectively.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
STAGE 1 STAGE 2 STAGE 3 STAGE 4
METABOLIC SYNDROME -NO
METABOLIC SYNDROME -YES
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PREVALENCE OF METABOLIC SYNDROME IN STAGE 2 AND 3 VERSUS
STAGE 1AND 4:
COPD
STAGE
METABOLIC
SYNDROME-YES
METABOLIC
SYNDROME-NO TOTAL
STAGE2,3 42 53.8%) 36 (46.2%) 78
STAGE 3,4 4 (18.2%) 18 (81.8%) 22
TOTAL 46 54 100
There is statistically significant difference  between prevalence of Metabolic
Syndrome between COPD stages 2 and 3 and stages 1 and 4 with p value  0.003.In our
study the prevalence of metabolic syndrome in stage 2 and 3 was 53.8 % and  in
stages 1 and 4 was 18.2%  with significant difference of p value 0.003.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
STAGE 2,3
42
36
STAGE1,4
4
18
METABOLIC SYNDROME -NO
METABOLIC SYNDROME -YES
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SOCIO ECONOMIC CLASS AND METABOLIC SYNDROME :
MODIFIED KUPPUSAMY SOCIO ECONOMIC SCALE:
TOTAL SCORE SOCIO ECONOMIC CLASS
26-29 UPPER (I)
16-25 UPPER MIDDLE (II)
11-15 LOWER MIDDLE (III)
5-10 UPPER LOWER (IV)
<5 LOWER (V)
SOCIO
ECONOMIC
CLASS
METABOLIC
SYNDROME –YES
METABOLIC
SYNDROME –NO TOTAL
LOWER MIDDLE
(III) 8 (34.8%) 15 (65.2%)
23
UPPER LOWER
(IV) 20 (50%) 20 (50%)
40
LOWER (V) 18(48.6%) 19 (51.4%) 37
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METABOLIC SYNDROME VERSUS SOCIOECONOMIC CLASS
There is no statistically significant difference  between prevalence of Metabolic
Syndrome in COPD patients in different SOCIO ECONOMIC CLASSES  with p
value of  0.466.
8
20 18
15
20
19
0
5
10
15
20
25
30
35
40
45
LOWER MIDDLE (III) UPPER LOWER (IV) LOWER(V)
METABOLIC SYNDROME - NO
METABOLIC SYNDROME - YES
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SMOKING AND METABOLIC SYNDROME:
SMOKING
METABOLIC
SYNDROME -
YES
METABOLIC
SYNDROME –NO TOTAL
YES 32(44.4%) 40 (55.6%) 72
NO 14 (50%) 14 (50%) 28
TOTAL 46 54 100
Metabolic Syndrome was almost equally prevalent in  both smoking and non
smoking COPD patients . It was 44.6% in smoking COPD patients and 50% in non
smoking COPD patients. So There is statistically NO significant difference  in
prevalence of Metabolic Syndrome between smoking COPD and non smoking COPD
patients in our study.
0%
10%
20%
30%
40%
50%
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100%
SMOKING -YES
32
40
SMOKING - NO
14
14
METABOLIC SYNDROME -NO
METABOLIC SYNDROME - YES
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HYPERTENSION VERSUS METABOLIC SYNDROME
HYPERTENSION
METBOLIC
SYNDROME –
YES
METABOLIC
SYNDROME –NO TOTAL
YES 27 (54%) 23 (46%) 50
NO 19 (38%) 31 (62%) 50
TOTAL 46 54 100
In our study the prevalence of  hypertension was 50% and prevalence of
Metabolic Syndrome was 54% in 50% of that hypertensive COPD patients and 38%
in non hypertensive patients .but there is  statistically no significant difference in
prevalence of Metabolic Syndrome between hypertensive and non hypertensive
COPD patients with p value of 0.108.
27
19
23
31
0
5
10
15
20
25
30
35
HYPERTENSION -YES HYPERTENSION -NO
METABOLIC SYNDROME -YES
METABOLIC SYNDROME -NO
70
IMPAIRED FASTING GLUCOSE VERSUS METABOLIC SYNDROME:
IMPAIRED
FASTING
GLUCOSE
METBOLIC
SYNDROME -
YES
METABOLIC
SYNDROME –NO TOTAL
YES 28 (56%) 22 (44%) 50
NO 18 (36%) 32 (64%) 50
TOTAL 46 54 100
The prevalence of impaired fasting glucose /diabetes in our study is 50%.out
of this 28 patients (56%) had metabolic syndrome but  18 patients with Metabolic
Syndrome does not had Impaired Fasting Blood Glucose in our study.There is
statistically  significant differnence in prevalence of Metabolic  Syndrome between
Impaired Fasting Glucose  and non impaired fasting  glucose COPD patients with p
value of 0.108.
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ABDOMINAL OBEYSITY VERSUS METABOLIC SYNDROME:
ABDOMINAL
OBEYSITY
METBOLIC
SYNDROME -
YES
METABOLIC
SYNDROME –NO TOTAL
YES 34 (77.3%) 10 (22.7%) 44
NO 12 (21.4%) 44 (78.6%) 56
TOTAL 46 54 100
The prevalence of Abdominal obesity in our study was 44%,out of which 34
patients(77.3%) had Metabolic Syndrome and 10 patients (22.3%)  with Abdominal
obesity does not had Metabolic Syndrome. 12 COPD patients with Metabolic
Syndrome does not have  abdominal obesity . There is  statistically  significant
differnence in prevalence of Metabolic  Syndrome between abdominal obese and non
abdominal obese  COPD patients with p value of < 0.001.
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BODY MASS INDEX VERSUS METABOLIC SYNDROME:
BODY MASS
INDEX
(BMI) ≥25 kg/m²
METBOLIC
SYNDROME –
YES
METABOLIC
SYNDROME –NO TOTAL
YES 29 (61.7%) 18 (38.3%) 47
NO 17 (32.1%) 36 (67.9%) 53
TOTAL 46 54 100
47% of COPD patients were overweight in our study out of  which 29 patients
had metabolic syndrome. But only 17 patients who had BMI less than 25 had
Metabolic Syndrome .There is  statistically  significant differnence in prevalence of
Metabolic Syndrome between over weight  and non over weight  COPD patients with
p value of 0.003.
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TRIGLYCERIDES VERSUS METABOLIC SYNDROME:
TRIGLYCERIDES
≥ 150mg/dl
METBOLIC
SYNDROME -
YES
METABOLIC
SYNDROME –NO TOTAL
YES 36 (72%) 14 (28%) 50
NO 10 (20%) 40 (80%) 50
TOTAL 46 54 100
50%  of our study population had elevated Triglycerides ,out of which 36
patients had Metabolic Syndrome but only 10 patients with out elevated Triglycerides
had Metabolic Syndrome . There is  statistically  significant difference in prevalence
of Metabolic Syndrome between elevated  Triglycerides   and non elevated
Triglycerides  COPD patients with p value of <0.001.
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HDL CHOLESTEROL VERSUS METABOLIC SYNDROME:
ELEVATED HDL
CHOLESTEROL
METBOLIC
SYNDROME –
YES
METABOLIC
SYNDROME –NO TOTAL
YES 35 (72.9%) 13 (27.1%) 48
NO 11 (21.2%) 41 (78.8%) 52
TOTAL 46 54 100
There is statistically significant difference in prevalence of Metabolic
Syndrome between low HDL cholesterol and normal HDL cholesterol  COPD patients
with p value of <0.001.
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PREVALENCE OF METABOLIC SYNDROME COMPONENTS IN COPD
PATIENTS :
METABOLIC SYNDROME
COMPONENT PREVALENCE
HYPERTENSION 50%
IMPAIRED FASTING GLUCOSE 50%
ABDOMINAL OBESITY 44%
ELEVATED TRIGLYCERIDES 50%
LOW HDL CHOLESTEROL 48%
50 50
44
50
48
4142
4344
4546
4748
4950
51
PREVALENCE OF METABOLIC SYNDROME
COMPONENTS
PREVALENCE OF METABOLIC
SYNDROME COMPONENTS
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C-REACTIVE PROTEIN VERSUS METABOLIC SYNDROME:
CRP METABOLICSYNDROME- YES
METABOLIC
SYNDROME-NO TOTAL
POSITIVE
>12mg/L 36(73.5%) 13( 26.5%) 49
NEGATIVE
(<12mg/L) 10(19.6%) 41(80.4%) 51
TOTAL 46 54 100
In our study  49% of COPD patients had elevated CRP and out of those 49% ,
36 patients (73.5%)  had  Metabolic  Syndrome.CRP was negative in 51% of COPD
patients and only 19.6% had Metabolic Syndrome among them. In our study There is
stastically significant difference  in prevalence of Metabolic Syndrome between CRP
positive and negative COPD patients with p value<0.001.
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COMPARISON BETWEEN COPD PATIENTS WITH METABOLIC
SYNDROME AND WITHOUT METABOLIC SYNDROME ACCORDING TO
PULMONARY FUNCTION TEST VALUES:
COMPONENT
METABOLIC
SYNDROME - YES
METABOLIC
SYNDROME-NO ‘P’ VALUEMEAN±(STANDARD
DEVIATION)
MEAN±(STANDARD
DEVIATION)
PRE FEV1(L) 1.7380(0.47818) 1.7413(0.57183) 0.976
PRE FEV1/FVC 0.53578(0.120622) 0.52222(0.142533) 0.612
POST FEV1(L) 1.8543 (0.47893) 1.8839(0.59631) 0.787
POST FEV1/FVC 0.5526(0.11480) 0.5476(0.14030) 0.847
In our study mean pre FEV1 and post FEV1 values in patients with metabolic
syndrome are 1.7380 and 1.8543L and without metabolic syndrome are 1.7413 and
1.8839 L respectively with out significant difference. Also mean PRE and POST
FEV1/FVC in patients with Metabolic Syndrome are 0.53578 and 0.5526 respectively
and without Metabolic Syndrome are 0.52222 and 0.5476 respectively without
significant difference.
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COMPARISON BETWEEN COPD PATIENTS WITH METABOLIC
SYNDROME AND WITHOUT METABOLIC SYNDROME ACCORDING TO
ANTHROPOMETRIC MEASUREMENTS:
COMPONENT
METABOLIC
SYNDROME – YES
METABOLIC
SYNDROME-NO ‘P’
VALUEMEAN±(STANDARD
DEVIATION)
MEAN±(STANDARD
DEVIATION)
HEIGHT
(cm) 162.54(6.292) 162.94(6.589) 0.757
WEIGHT
(kg) 67.87(8.387) 63.46(6.521) 0.004
WAIST
CIRCUMFERENCE
(cm)
93.43(9.809) 86.57(5.524) <0.001
HIP
CIRCUMFERENCE
(cm)
97.78(8.710) 93.00(6.969) 0.003
BMI
(kg/m²) 25.75228(2.88857) 23.92278(2.241455) 0.001
WAIST HIP RATIO
(WHR) 0.955483(0.0504074) 0.932167(0.0445064) 0.008
79
COMPARISON BETWEEN COPD PATIENTS WITH METABOLIC
SYNDROME AND WITHOUT METABOLIC SYNDROME ACCORDING TO
AGE AND TOTAL COUNT:
COMPONENT
METABOLIC
SYNDROME – YES
METABOLIC
SYNDROME-NO
‘P’ VALUE
MEAN±(STANDARD
DEVIATION)
MEAN±(STANDARD
DEVIATION)
AGE
(years) 61.85(7.622) 60.65(8.117) 0.451
TOTAL WBC
COUNT
Cells /cumm) 9258.70(1883.092) 5437.04(1501.860) <0.001
In our study Mean age in patients with Metabolic Syndrome is 61.85 years and
without Metabolic Syndrome is 60.65 years without significant difference between
two groups. But mean total WBC count in Metabolic Syndrome group is 9258.70 cells
/cu mm and patients without Metabolic Syndrome group is 5437.04 cells /cu mm with
significant difference between  two groups with p value of <0.001.
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COMPARISON BETWEEN COPD PATIENTS WITH METABOLIC
SYNDROME AND WITHOUT METABOLIC SYNDROME ACCORDING TO
FASTING BLOOD GLUCOSE :
COMPONENT
METABOLIC
SYNDROME – YES
METABOLIC
SYNDROME-NO ‘P’
VALUEMEAN±(STANDARD
DEVIATION)
MEAN±(STANDARD
DEVIATION)
FASTING BLOOD
GLUCOSE
( mg/dl) 102.87(11.623) 96.74(11.176) 0.009
In our study mean fasting blood glucose is 102.87mg/dl in patients with
metabolic syndrome and 96.74mg/dl in patients without metabolic syndrome with
significant difference between two groups with p value of 0.009.
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DISCUSSION:
GENDER DISTRIBUTION:
In our study ,the study population predominantly consists of male patients
(82%) because the important risk factor smoking is most common among males than
females. Hence  COPD is more in males compared to females .A study by Neveen
Mahmoud Ameen et al(39) all the study population was only males but  in a study by
Marie-Kathrin Breyer et al(50) 59% of study population were male subjects.
BASELINE CHARACTERISTICS OF COPD PATIENTS IN OUR STUDY:
In our study minimum age and maximum age of the patients are  41 years and
75 years respectively  because according to GOLD guideline the diagnosis of  COPD
is considered only in persons aged above 40 years. In a study by vujic T et al (51) the
mean  age of COPD patients was  62.73±( SD- 7.26) years , in our study it is
61.20±(SD-7.877) years. The mean BMI and waist circumference in that study was
24.63±(SD-5.3)(kg/m²) and 93.23±(SD-11.94)(cm) respectively, in our
study it was24.76± (SD-2.70) and  89.73± (SD-8.478) kg /m².
In a study by vujic et al (51), Mean  systolic and diastolic blood pressure was
125.58±22.5 and 78.27±10.29 respectively. In our study it was 131.29±(SD-14.451)
and 83.64±(SD-8.102) mmHg respectively. Mean systolic and diastolic blood pressure
was comparatively higher in our study patients. In a study  conducted by marie –
kathrin bayer et al(50) ,mean fasting blood glucose  was 104.50±(SD-21.62) mg/dl but
in our study it was 99.56±(SD- 11.735) mg/dl which is  comparatively lower in our
study population.(51)
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In our study mean triglyceride and HDL levels was 158.19±(SD-29.984) mg/dl
and 40.92±(SD-5.590) mg/dl respectively but  in a study by Lokendra Dave et al(52)
on Metabolic Syndrome in COPD patients, mean Triglyceride and HDL cholesterol
levels were 136.04±(SD-52.6mg/dl) and 37.22±(SD-9.00) mg/dl respectively . HDL
and triglyceride levels  in our study population are higher compared to the dave et
al(52) study  population. Mean total WBC count which is a significant marker of
underlying  inflammation , is 7195±(SD- 2546.353)cells cu mm in our study
population but in  a study by vujic et al (51),the mean total WBC count was
9700±(SD-2700) cells mm ³ which was high compared to our study population.
In a study by vujic et al(51) mean LDL cholesterol was 53.1531 mg/dl  and
mean total cholesterol was 85.405mg/dl but in(51) our study it is  88.55 and
160.64mg/dl respectively .Both LDL and total cholesterol are significantly higher in
our study population  compared to vujic et al (51)study population.
STAGING OF COPD IN OUR STUDY POPULATION:
In our study maximum number of patients are from stage two and three
consisting 78% study population . In a study by vujic et al(51) stage two and three
patients consists of 41.8 and 38.8% Respectively which is similar to our study
population . In that study stage 1 and 4 consists of 6.1% and 13.3% respectively.
But in our study it was 15% and 7% respectively. The possible explanation for
low number of stage 1patients are delay in seeking medical advice and delay in
diagnosing  the disease .More the disease severity more chance of  hospitalization  in
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intensive care unit is the reason for low number of  stage 4 study population in our
study.
PREVALENCE OF METABOLIC SYNDROME IN COPD PATIENTS:
In our study population Metabolic Syndrome was prevalent in 46% of COPD
patients which indicates three or more components of Metabolic Syndrome were
present in these patients. A study by marie kathrin bayer et al(50) the prevalence was
57% which higher prevalence compared to our study but lokendra Dave et al (52)
study it was 42% similar to our  study.
DISTRIBUTION OF METABOLIC SYNDROME COMPONENTS IN COPD
PATIENTS:
In our study only one patient had all five components of Metabolic Syndrome
where as Seven patients does not have any components of Metabolic Syndrome.15
patients had only one component and 32 patients had two component of the Metabolic
Syndrome. These 47 patients who were all had one or two component of the
Metabolic Syndrome may develop Metabolic Syndrome in near future and increases
the cardio vascular disease risk in these patients. Hence screening for Metabolic
Syndrome is needed in these patients .
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PREVALENCE OF METABOLIC SYNDROME IN DIFFERENT COPD
STAGES
The prevalence of Metabolic Syndrome was 20% , 53.6 %, 54.5 %,14.3 % in
stage 1 ,stage 2,stage 3 and stage 4 COPD respectively. In a study by Therese Ghatas
et al(53) it  was  40% , 53.40%, 30%, 28.50% in stage 1 ,stage 2, stage 3 and stage 4
COPD respectively. The incidence was higher in stage 1 and stage 2 compared to our
study in which incidence was higher in stage 2 and stage 3 COPD patients.
There is statistically significant different between prevalence of Metabolic
Syndrome between  COPD stages 2 and 3 and stages 1 and 4 with p value 0.003.In our
study the prevalence of Metabolic Syndrome in stage 2 and 3 was 53.8 % and stage 1
and 4 was 18.2%  with significant difference p value 0.003.
This significant prevalence  of Metabolic Syndrome indicates the importance
for Metabolic Syndrome screening in stage two and  three  COPD patients for
Metabolic Syndrome .Various studies conducted across the world has confirmed the
above  findings.
METABOLIC SYNDROME VERSUS SOCIOECONOMIC CLASS:
In our study  most of the study population were in  upper lower and lower socio
economic class (IV and V) 77% and another 23% from lower middle class . Low socio
economic status is one of the important risk factors  for COPD due to overcrowding
and repeated respiratory tract infections  which corresponds well with our study
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population. The prevalence of Metabolic Syndrome was 34.8% ,50%,48.6% in class
III,IV,V respectively without significant p value of 0.466.
SMOKING AND METABOLIC SYNDROME:
Metabolic Syndrome was almost equally prevalent in both smoking and non
smoking COPD patients .it was 44.6% in smoking COPD patients and 50% in non
smoking COPD patients. In our study , There is statistically NO significant difference
in prevalence of Metabolic Syndrome between smoking COPD and non smoking
COPD patients with p value 0.617.But various studies had found that Metabolic
Syndrome was significantly higher in smoking COPD patients than patients without
smoking .
HYPERTENSION VERSUS METABOLIC SYNDROME:
In a study by  therese ghatas(53) hypertension was  prevalent in 70.4% COPD
patients and in another study by naveen  mahmoud  ameen et al (39)it was 31.4%In
our study the prevalence of hypertension was 50% and prevalence of Metabolic
Syndrome was 54% in that 50% of  hypertensive COPD patients and 38% in non
hypertensive patients .
FASTING BLOOD GLUCOSE VERSUS METABOLIC SYNDROME :
In a study by lokendra dave et al(52) the prevalence of Fasting Blood Glucose
was 66% , in our study it was 50%  which was comparatively lower than the above
study. But in  a study by Therese Ghatas et al (53) it was42.60% which was  similar
to our study. In  Another study by N.M.Ameen et al(39) it was 57.1%. The prevalence
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of impaired fasting glucose /diabetes in our study was 50%,out of this 28 patients
(56%) had metabolic syndrome and 22 patients (44%) doesnot have etabolic
Syndrome.  But 18 patients with Metabolic Syndrome had normal Fasting Blood
Glucose in our study.
ABDOMINAL OBESITY VERSUS METABOLIC SYNDROME:
In Therese Ghatas et al(53) study the prevalence was 51.10%  and  in Marie-
Kathrin Breyer(50) study it was 49%. In our study , the prevalence of  abdominal
obesity was  44%,out of which 34 patients (77.3%) had Metabolic Syndrome  and 10
patients 22.3% with abdominal obesity does not  have  Metabolic Syndrome. But only
12 COPD patients with Metabolic Syndrome did not have  abdominal obesity .
BODY MASS INDEX VERSUS METABOLIC SYNDROME:
In a study by Therese Ghatas et al(53) the prevalence of Metabolic Syndrome
in COPD patients with BMI <25kg/m²  was 29% and BMI > 25kg/m² was 77% but in
our study it was  32.1% and 61.7% respectively which is almost  similar to the above
study with significant difference between two groups.
HDL CHOLESTEROL AND METABOLIC SYNDROME :
In our study, the prevalence of low HDL cholesterol is 48%. In a  study by
lokendra dave et al (52) the prevalence of low HDL was 70% which was
comparatively higher than our study population but in  another study by N.M. Ameen
et al(39), the prevalence was 35.7% which was  comparatively lower than our study
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population. In our study 72.9% of patients with low HDL cholesterol had Metabolic
Syndrome and 21.2% of patients with normal HDL cholesterol had Metabolic
Syndrome with significant difference between two groups .
TRIGLYCERIDES AND METABOLIC SYNDROME :
In our study, the prevalence of elevated triglycerides is 50%.  A study by
lokendra dave et al (52)the prevalence of elevated triglycerides was 46% which was
comparatively lower  than our study population but another study by N.M. Ameen et
al(39), the prevalence was 51.4% which was similar to our study population. In our
study 72.0% of patients with elevated triglycerides have Metabolic Syndrome and
20.0% of patients who does not have elevated triglycerides have Metabolic syndrome
with significant different between two groups.
C-REACTIVE PROTEIN AND METABOLIC SYNDROME :
In a study by  therese ghatas  et al(53) CRP was elevated in 54% of COPD
patients and out of those 54% patients 84% of patients had Metabolic Syndrome.
Similar to that study,  our study also 49% of COPD patients had elevated CRP and out
of those 49%,36 patients (73.5%) had  Metabolic Syndrome.CRP was negative in 51%
of COPD patients and only 19.6% had Metabolic Syndrome  among them with
significant different between CRP positive and negative groups .
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COPD PATIENTS WITH METABOLIC SYNDROME AND WITHOUT
METABOLIC SYNDROME ACCORDING TO PULMONARY FUNCTION
TEST AND LIPID PROFILE VALUES:
In a study by T vujic et al(51), mean post Bronchodilatation  (FEV1/FVC ) in
COPD patients with Metabolic Syndrome and without Metabolic Syndrome are
0.5239, and 0.4541 respectively with significant difference between two groups. But
in our study it was 0.5526 and 0.5476without significant between two groups.
In a study by Neveen  Mahmoud Ameen et al (39), mean HDL cholesterol level
in COPD patients with Metabolic Syndrome and without Metabolic Syndrome was
40.7 and 53.2 mg/dl respectively with significant difference between two groups. In
our study it was 39.30 and 42.30 mg/dl with significant difference between two
groups. HDL cholesterol level was comparatively lower in Metabolic Syndrome
patients group in our study which was similar to above mentioned  study .
In a study by Neveen  Mahmoud Ameen et al (39) mean Triglycerides  level in
COPD patients with Metabolic Syndrome and without Metabolic Syndrome was
226.7 and 158 mg/dl respectively with significant difference between two groups. In
our study it was 169.22 and 148.20 mg/dl with significant difference between two
groups . Triglyceride level was comparatively higher in Metabolic Syndrome patients
group in our study which was similar to above mentioned study .
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COPD PATIENTS WITH METABOLIC SYNDROME AND WITHOUT
METABOLIC SYNDROME ACCORDING TO ANTHROPOMETRIC
MEASUREMENTS AND AGE :
In a study by Neveen  Mahmoud Ameen et al (39) BMI in COPD patients with
Metabolic Syndrome and without Metabolic Syndrome was 29.2 and 22.5 kg/m²
respectively with significant difference between two groups. In our study it was 25.75
and 23.92 kg/m² with significant difference between two groups. BMI was
comparatively  lower in Metabolic Syndrome patients group in our study than above
mentioned study . In another study by vujic et al(51), it was 30.0 and 24.88 kg/m²
respectively which was similar to Neveen  Mahmoud Ameen et al(17) study and
higher than our study population .
In a study by vujic T et al (51), waist circumference  in COPD patients with
Metabolic Syndrome and without Metabolic Syndrome was 106.78 cm and 93.90 cm
respectively with significant difference between two groups. In our study it was93.40
and 86.57 cm with significant difference between two groups  compared to that stud,
in our study population had  reduced waist circumference one possible reason for it
was low socio economic class in which under nutrition is more common.
In a study by vujic T et al(51), mean age in COPD patients with Metabolic
Syndrome and without Metabolic Syndrome was 63.43 years and 65.70 years
respectively without significant difference between two groups. In our study it was
61.85and 60.65 years without significant difference between two groups .
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COPD PATIENTS WITH METABOLIC SYNDROME AND WITHOUT
METABOLIC SYNDROME ACCORDING TO FASTING BLOOD
GLUCOSEAND TOTAL COUNT:
In a study by vujic T et al(51), mean total count in  COPD patients with
Metabolic Syndrome and without Metabolic Syndrome was 9,560 and 8280 cell/cu
mm respectively with significant difference between two groups.  In our study it was
9258and 5437 cells/cu mm with significant difference between two groups .Our study
results is similar to the above mentioned study ,the reason being those  people with
Metabolic Syndrome will have more systemic  inflammation than people without
Metabolic Syndrome.
In a study by vujic T et al (51), mean FBS in COPD patients with Metabolic
Syndrome and without metabolic syndrome was 116.75 and 94.59 mg/dl  respectively
with significant difference between two groups.  In a study by Neveen  Mahmoud
Ameen et al(39), FBS in COPD patients with Metabolic Syndrome and without
Metabolic Syndrome was 115.3 and 92.9 mg/dl respectively with significant
difference between two groups. In our study it was 102.87 and 96.74 mg/dl with
significant difference between two groups . Compared to above studies, our study
population with metabolic syndrome and  without Metabolic Syndrome have similar
FBS values.
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CONCLUSIONS AND RECOMMENDATIONS:
Between October 2017 and September 2018, 100 COPD  patients who
attended Thoracic Medicine outpatient department in Government Vellore
Medical College & Hospital were analysed for metabolic syndrome and systemic
inflammatory markers
1. In our study the prevalence of Metabolic Syndrome was 46% in  COPD patients.
The prevalence of Metabolic Syndrome in stage two and three COPD
patients was 53.8% and stage one and four was 18.2% with significant
difference between the two groups. So every COPD patient attending   Thoracic
Medicine outpatient department must be screened for Metabolic Syndrome
particularly in stage two and stage three  as they are at increased risk for
developing of Metabolic Syndrome .
2. In our Study the prevalence of  Abdominal  obesity , Hypertension, Impaired
Fasting Glucose ,  Elevated Triglycerides ,Low HDL cholesterol are 44%,  50%,
50%, 50%, 48% respectively. Compared to other studies conducted across the
world where abdominal obesity was the most common component , In our study
Hypertension , Diabetes and  Dyslipidemia were the most common components .
So screening for non communicable diseases which is already implemented in our
department should be strengthened to identify COPD patients with undiagnosed
Hypertension ,Dyslipidemia and diabetes mellitus.
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3. In our study inflammatory Markers  like  C Reactive Protein and  ,total WBC
count were  elevated in patients with metabolic Syndrome  than patients
without Metabolic  Syndrome with p value <0.05. Measuring  systemic
inflammatory markers like C REACTIVE PROTEIN (CRP) and total  WBC
count is comparatively easy and cost  effective and easily available in rural
health settings than other systemic inflammatory markers like Interlukin -6 (IL-
6) and TNF -α  . Hence these markers should be measured in COPD patients to
diagnose the underlying  systemic inflammation and to predict the persons who
are all at risk for developing metabolic syndrome in COPD patients
6. The prevalence of Abdominal Obesity ,Hypertension, Fasting Blood Glucose,
Elevated  Triglycerides , Low HDL cholesterol were higher in patients with
Metabolic Syndrome than  patients without Metabolic Syndrome with
significant difference  between two groups. Hence COPD  patients  with
Dyslipidemia, Impaired Fasting Glucose /Diabetes Mellitus and Hypertension
should be started on ideal antihypertensive drugs , oral hypoglycaemic
drugs/insulin and   lipid lowering drugs  early and should be  counselled
regarding  life style modifications and dietary habits to prevent the
cardiovascular disease  and chronic complications of diabetes and hypertension
and  by implementing these measures we can reduce morbidity and mortality in
COPD patients
7. Body Mass Index , Hip Circumference, Weight, Waist Hip Ratio, VLDL
cholesterol were significantly higher in patients with Metabolic Syndrome
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than  patients without Metabolic Syndrome. Age, Gender ,Smoking , Height,
Total Cholesterol, LDL cholesterol, Socio Economic Class, Pre and post
Bronchodilatation  [ FEV1,( FEV1/FVC)],  were not Significantly different
between patients with Metabolic Syndrome and patients without Metabolic
Syndrome. One last and most  important factor related to both  COPD patients
and Metabolic Syndrome is smoking and physical inactivity ,so every patient
should  be   counselled regarding ill effects of smoking  and  physical
inactivity and  measures should be taken to avoid smoking and advised
regarding  regular physical exercise .
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3. SEX :               MALE                      FEMALE
4. OCCUPATION :
5. ADDRESS :
6. OP NO. :
7. SOCIO ECONOMIC CLASS        :
8. SMOKING                                    :
9. HYPERTENSION                         :                       YES                      NO
10. SYSTOLIC BP :
11. DIASTOLIC BP :
12. FASTING BLOOD GLUCOSE :
13. DIABETES : YES                          NO
14. HEIGHT : WEIGHT : BMI:
15. WAIST CIRCUMFERENCE : HIP CIRCUMFERENCE:
16. WAIST HIP RATIO :
17. HDL CHOLESTEROL : VLDL CHOLESTEROL:
18. TRIGLYCERIDE : TOTAL CHOLESTEROL:
19. LDL CHOLESTEROL :
20. C –REACTIVE PROTEIN :
21.    UREA/ CREATININE :
22. CHEST XRAY :
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23. TOTALWBC COUNT :
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25. METABOLIC SYNDROME :    YES                    NO
26. PRE BRONCHODILATATION - FEV1:                      FEV1/FVC
27. POST BRONCHO DILATATION - FEV1:                       FEV1/FVC
28.TOTAL NO OF COMPONENTS OF METABOLIC SYNDROME      :
29. METABOLIC SYNDROME              :    YES                    NO
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M
Y 70 161 27.01 92 0.958 120 80 n 198 33 39.6 33 106 4300 Y 2.11 0.6 2.21 0.62 2 Y 5
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82 vijayan 57 M Y 60 149 27.03 92 0.978 158 92 y 156 37 31.2 45 113 11000 Y 1.92 0.59 2.08 0.62 2 Y 4
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84 bagiyammal 63
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F
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95 poongavanam 71
F
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0
sarala 51 F N 62 160 24.22 79 0.918 110 70 n 187 55 37.4 77 169 4500 N 1.56 0.56 1.69 0.58 2 N 5
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KEY TO MASTER CHART:
• BMI – BODY MASS INDEX
• WC – WAIST CIRCUMFERENCE
• WHR – WAIST HIP RATIO
• SBP – SYSTOLIC BLOOD PRESSURE
• DBP – DIASTOLIC BLOOD PRESSURE
• HT – HYPERTENSION
• TGL – TRIGLYCERIDE
• HDL – HIGH DENSITY LIPOPROTEIN
• LDL – LOW DENSITY LIPOPROTEIN
• TC – TOTAL CHOLESTEROL
• CRP – C REACTIVE PROTEIN
• SEC – SOCIO ECONOMIC CLASS
• MS – METABOLIC SYNDROME
• FEV1- FORCED EXPIRATORY VOLUME 1
• FVC – FORCED VITAL CAPACITY
• M – MALE
• F – FEMALE
• Y – YES
• N - NO
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PATIENT CONSENT FORM
STUDY DETAIL: “A CROSS SECTIONAL STUDY ON THE PREVALENCE OF
METABOLIC SYNDROME IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE  PATIENTS IN GOVERNMENT VELLORE
MEDICAL COLLEGE AND HOSPITAL, VELLORE”
STUDY CENTRE:
PATIENT’S NAME:
PATIENT’S AGE:
IDENTIFICATION NUMBER:
I confirm that I have understood the purpose and procedure of the above study.
I have the opportunity to ask questions and all my questions and doubts have been
answered to my complete satisfaction.
I understand that my participation in the study is voluntary and that I am free to
withdraw at any time without giving reason, without my legal rights being affected.
I understand that the sponsor of the clinical study, others working on the
sponsor’s behalf, the ethical committee and the regulatory authorities will not need my
permission to look at my health records, both in respect of the current study and any
further research that may be conducted in relation to it, even if I withdraw from the
study I agree to this access. However I understand that my identity would not be
revealed in any information released to third parties or published, unless as required
under the law. I agree not to restrict the use of any data or results that arise from this
study.
I hereby consent to participate in this study.
I hereby give permission to undergo complete clinical examination and
diagnostic tests including haematological, biochemical, radiological tests.
Signature/thumb impression:
Patient’s name and address:                                             Place: Date:
Signature of the investigator:
Name of the investigator:                                                  Place:                              Date
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